Company profile
- Industry
- Pharmaceuticals
- Founded
- 1892
- Headquarters
- Stamford, United States
- Ownership
- In Chapter 11 bankruptcy proceedings
Profiles are auto-generated and infrequently updated.
The analyses
The Crisis Response · Decision Forks
Purdue's Playbook: Settle Small, Withdraw $11 Billion, Buy Permanent Immunity
Purdue pleaded guilty in 2007, paid $634 million, and kept defrauding the DEA for another decade. The crisis response wasn't denial-gone-wrong - it was a deliberate playbook to settle small, withdraw $11 billion, and buy permanent immunity. It failed only at the Supreme Court.
8 min
The Engineered Outcome · Business Model
Purdue Pleaded Guilty Again in 2020: The Misconduct Ran From 2007 to at Least 2017
The story is that Purdue was caught in 2007 and stopped. It wasn't. Purdue LP pleaded guilty again in 2020 for misconduct running from May 2007 through at least March 2017—and the engine was a five-sentence letter, a label phrase, and a sales force it called its most valuable resource.
8 min
The Fall · Crisis & Reinvention
Purdue's 2007 Reckoning Ended in Misdemeanors — the $11 Billion Escape Hatch Held Until 2024
OxyContin killed across two decades while the people who profited stayed untouched. The 2007 'reckoning' fined a subsidiary and gave executives misdemeanors. It took until a 5-4 Supreme Court ruling in 2024 to close the escape hatch on $11 billion.
8 min
The Fall · Decision Forks
After a Six-Year Legal Maze, a 5–4 Ruling Raised the Sacklers' Purdue Deal to $7.4 Billion
The popular story says the Sacklers were brought to justice. The real one: a six-year legal maze that nearly bought the family permanent immunity for $4.3 billion, until a 5–4 Supreme Court ruling forced a third deal worth $7.4 billion.
8 min